Co-crystal forms of selinexor
The present invention is directed to selinexor co-crystal forms; more particularly to two co-crystal forms with succinic acid as the coformer and a co-crystal form with vanillin as the coformer. The present disclosure is also related to processes for the preparation of selinexor co-crystal forms. Further, the present invention also relates to pharmaceutical compositions comprising a selinexor co-crystal form and method for treating disease using a selinexor co-crystal form.
1 . A selinexor co-crystal comprising selinexor and succinic acid as a coformer.
2 . The selinexor co-crystal of claim 1 , wherein the selinexor co-crystal is crystalline Form I characterized by X-ray powder diffraction peaks at 2θ angles of about 5.2°, 16.7°, 17.0°, 17.6°, and 19.7°.
3 . The selinexor co-crystal of claim 2 , having one to three thermal events with onsets selected from about 121° C., 146° C. and 161° C., as measured by differential scanning calorimetry.
4 . The selinexor co-crystal of claim 1 , characterized by having one or more X-ray powder diffraction peaks selected from 2θ angles of about 5.2°, 16.7°, 17.0°, 17.6° and 19.7°.
5 . The selinexor co-crystal of claim 1 , characterized by having two or more X-ray powder diffraction peaks selected from 2θ angles of about 5.2°, 16.7°, 17.0°, 17.6° and 19.7°.
6 . The selinexor co-crystal of claim 1 , wherein the selinexor co-crystal is crystalline Form II characterized by X-ray powder diffraction peaks at 2θ angles of about 10.4°, 16.6°, 18.9°, and 20.7°.
7 . The selinexor co-crystal of claim 6 , having a thermal event with an onset at about 155° C., as measured by differential scanning calorimetry.
8 . The selinexor co-crystal of claim 1 , characterized by having one or more X-ray powder diffraction peaks selected from 20 angles of about 10.4°, 16.6°, 18.9°, and 20.7°.
9 . The selinexor co-crystal of claim 1 , characterized by having one or more X-ray powder diffraction peaks selected from 2θ angles of about 10.4°, 16.6°, 18.9°, and 20.7°.
10 . A selinexor co-crystal comprising selinexor with vanillin as a coformer.
11 . The selinexor co-crystal of claim 10 , wherein the selinexor co-crystal is crystalline Form I characterized by having X-ray powder diffraction peaks at 2θ angles of about 12.6°, 15.8°, and 19.0°.
12 . The selinexor co-crystal of claim 11 , characterized by having X-ray powder diffraction peaks at 2θ angles of about 12.6°, 14.8°, 15.8°, 19.0°, 20.2°, 25.4°, and 27.9°.
13 . A process for the preparation of selinexor co-crystal of claim 2 , comprising
a) mixing a solution of saturated selinexor and solution of saturated succinic acid in ethyl formate in about 1 (selinexor in ethyl formate): 1 (succinic acid in ethyl formate) mL ratio to form a mixed solution of selinexor and succinic acid in ethyl formate;
b) adding to the mixed solution of selinexor and succinic acid in ethyl formate solid selinexor and solid succinic acid in a ratio of about 1 mL (mixed solution of selinexor and succinic acid in ethyl formate): 0.25 mmol (solid selinexor): 0.375 mmol (solid succinic acid) solid succinic acid;
c) slurrying the mixed solution with the added selinexor and succinic acid; and
d) cooling the solution to yield the selinexor co-crystal.
14 . A process for the preparation of selinexor co-crystal of claim 6 , comprising
a) mixing a solution of selinexor and solution of succinic acid, wherein the solvent of the solution of selinexor or succinic acid is selected from the group consisting of ethyl formate, methanol, 1-propanol, ethyl acetate, isopropanol and acetone, or mixture thereof; to form a mixed solution of selinexor and succinic acid, wherein the ratio of mmol of selinexor:mmol of succinic acid:mL of solvent for selinexor:mL of solvent for succinic acid is about 1 mmol (selinexor): 1-1.5 mmol (succinic acid): 3-4 mL (solvent for selinexor): 3-4 mL (solvent for succinic acid) solvent for succinic acid,
b) adding to the mixed solution of selinexor and succinic acid an anti-solvent, wherein the ratio of mL of mixed solution for selinexor and succinic acid:mL of anti-solvent is about 1 mL (mixed solution for selinexor and succinic acid): 2-4 mL (anti-solvent) anti-solvent; and
c) cooling the mixture of step b) to yield the selinexor co-crystal.
15 . A process for preparing selinexor co-crystal of claim 10 , comprising
a) mixing a solution of dissolved selinexor and solution of dissolved vanillin in tetrahydrofuran in about 1 (selinexor in tetrahydrofuran): 1 (vanillin in tetrahydrofuran) mL ratio to form a mixed solution of selinexor and vanillin in tetrahydrofuran;
b) adding to the mixed solution of selinexor and vanillin in tetrahydrofuran solid selinexor and solid vanillin in a ratio of about 1 mL (mixed solution of selinexor and vanillin in tetrahydrofuran) mixed solution of selinexor and vanillin in tetrahydrofuran: 0.25 mmol (solid selinexor) solid selinexor: 0.26 mmol (solid vanillin) solid vanillin;
c) slurrying the mixed solution with the added selinexor and vanillin; and
d) cooling the solution to yield the selinexor co-crystal.
16 . The selinexor co-crystal of claim 2 , characterized by having X-ray powder diffraction peaks at 2θ angles of about 5.2°, 10.4°, 16.7°, 17.0°, 17.6°, 19.5°, 19.7°, 20.4°, 21.8°, and 22.9°.
17 . The selinexor co-crystal of claim 2 , characterized by having X-ray powder diffraction peaks at 2θ angles of about 5.2°, 7.1°, 10.4°, 11.3°, 12.1°, 16.7°, 17.0°, 17.6°, 19.5°, 19.7°, 20.4°, 21.8°, and 22.9°.
18 . The selinexor co-crystal of claim 6 , characterized by having X-ray powder diffraction peaks at 2θ angles of about 5.7°, 10.4°, 14.2°, 16.6°, 18.9°, 20.7°, 21.4°, 22.2°, 23.0°, 24.5°, 25.9°, 26.6°, and 27.6°.
19 . The selinexor co-crystal of claim 6 , characterized by having X-ray powder diffraction peaks at 2θ angles of about 5.7°, 10.4°, 16.6°, 18.9°, 20.7°, 21.4°, 24.5°, 26.6°, and 27.6°.